profit from every $100 of sales.
$0$100
Nuvation Bio
$4.29+2.14% today
-13.9% in 1 year
1-year low $4.051-year high $9.54
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Nuvation Bio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $62.9 million in 2025, with -$205 million of profit last year.
SalesProfit
Nuvation Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nuvation Bio | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Nuvation Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 8 | 63 | |
| – | 0 | 1 | 54 | |
| -120 | -100 | -168 | -213 | |
| -120 | -76 | -567 | -189 | |
| -104 | -76 | -568 | -205 | |
| -0.48 | -0.35 | -2.11 | -0.60 | |
| – | – | 10.1% | 85.2% | |
| – | – | -2,128.2% | -338.7% | |
| – | – | -7,213.8% | -325.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 672 | 621 | 541 | 595 |
| Cash | 101 | 43 | 36 | 164 |
| Total debt | 4 | 4 | 9 | 57 |
| Total liabilities | 17 | 16 | 77 | 289 |
| 655 | 605 | 464 | 306 | |
| 217 | 219 | 269 | 342 | |
| -14.3% | -9.8% | -94.9% | -41.5% | |
| -15.9% | -12.5% | -122.5% | -66.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -96 | -68 | -130 | -173 | |
| 0 | 0 | 0 | 8 | |
| -96 | -68 | -131 | -182 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 16 | 20 | 32 | 36 |
Valuation
- –
- –
- –
- 4.7×
- 24.1×
- –
- –
- -12.0%
- -13.5%
- 0.0%
Profitability
- 85.2%
- -338.7%
- -325.3%
- -96.8%
- -27.9%
- -45.0%
- -44.1%
- -23.9%
- -28.3%
- 87.8%
Growth
- +699.0%
- –
- −33.1%
- –
- +14.6%
Financial health
- -0.6×
- 0.03
- 1.6%
- -10.5×
- 7.44
- 7.24
- 0.23
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 959
Bottom 8%of 987
What analysts expect
- Average price target
- $12.40
- Range
- $10.00 – $17.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | 0.01 | 0.12 | −91.7% |
| Mar 2, 2026 | -0.11 | -0.11 | +0.0% |
| Nov 3, 2025 | -0.16 | -0.17 | +5.9% |
| Aug 7, 2025 | -0.17 | -0.17 | +0.0% |
| May 7, 2025 | -0.16 | -0.16 | +0.0% |
| Mar 6, 2025 | -0.15 | -0.14 | −7.1% |
| Nov 6, 2024 | -0.15 | -0.13 | −15.4% |
| Aug 5, 2024 | -0.15 | -0.06 | −150.0% |
News
Nuvation Bio rises as Cantor initiates at overweightSeeking Alpha · Aug 21, 2026The newest story we have is from Aug 21, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
42No pass
Philip Fisher
47No pass
Peter Lynch
51No pass
Joel Greenblatt
2No pass
Charlie Munger
39No pass
Terry Smith
37No pass
Questions about Nuvation Bio
Is Nuvation Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nuvation Bio AI analysis
What does Nuvation Bio do?
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is in Biotechnology.
Does Nuvation Bio pay a dividend?
No. Nuvation Bio does not pay a dividend at the moment.
Is Nuvation Bio stock halal?
Questionable. Nuvation Bio sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Nuvation Bio stock done over the past year?
Down 13.9% over the past twelve months, to $4.29. It traded between $4.05 and $9.54 and is 55.0% below its high.
Who are Nuvation Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Nuvation Bio's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.